^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    tesevatinib (KD019)

    i
    Other names: KD-019, KD019 , XL647, XL 647, PRIM-001 , XL7647
    Company:
    Sanofi
    Drug class:
    EGFR inhibitor, HER2 inhibitor, VEGFR inhibitor, EphB4 inhibitor
    Related drugs:
    3years
    In vivo efficacy of tesevatinib in patient-derived xenograft glioblastoma models may be limited by tissue binding and compensatory signaling. (PubMed, Mol Cancer Ther)
    Overall, tesevatinib efficacy in EGFR amplified PDX GBM models is robust in vitro but relatively modest in vivo, despite a high brain-to-plasma ratio. This discrepancy may be explained by drug-tissue binding and compensatory signaling.
    Preclinical • Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1)
    |
    EGFR amplification
    |
    tesevatinib (KD019)
    almost4years
    Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P2, N=40, Completed, Kadmon Corporation, LLC | Active, not recruiting --> Completed
    Clinical • Trial completion
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR amplification
    |
    tesevatinib (KD019)
    4years
    Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Kadmon Corporation, LLC | Trial primary completion date: Jan 2020 --> Mar 2020
    Clinical • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR amplification
    |
    tesevatinib (KD019)
    over4years
    Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases (clinicaltrials.gov)
    P2, N=36, Completed, Kadmon Corporation, LLC | Trial completion date: Aug 2018 --> Jan 2019 | Trial primary completion date: Aug 2018 --> Jan 2019
    Clinical • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    tesevatinib (KD019)